论文部分内容阅读
目的研究肝移植供体CYP3A5基因MDR1基因多态性与受体术后他克莫司血药浓度/给药剂量的关系。方法对39例肝移植患者受体术后他克莫司血药浓度检测。特异性等位基因扩增法和聚合酶链反应结合限制性片段长度多态性分析法分别检测供体CYP3A5和MDR1基因型,按基因型分组比较供体基因多态性与受体他克莫司用药关系。结果 39例肝移植患者供体基因型CYP3A5:*3/*3型12例,*1/*3型8例,*1/*1型19例;MDR1:T/T型13例,C/T型18例,C/C型8例。结论肝移植病人供体的CYP3A5基因多态性与受体他克莫司血药浓度具有相关性。研究CYP3A5供体基因多态性,有利于移植病人术后他克莫司个体化用药方案的制定;但是供体MDR1基因对他克莫司的受体个体化用药影响不大。
Objective To investigate the relationship between polymorphism of MDR1 gene in CYP3A5 gene and the plasma concentration of tacrolimus after administration and the dose of CYP3A5. Methods Tacrolimus plasma concentration was measured in 39 patients with liver transplantation. Specific allele amplification and polymerase chain reaction combined with restriction fragment length polymorphism analysis were used to detect the donor CYP3A5 and MDR1 genotypes by genotyping group compared donor gene polymorphism with the receptor tacrolimus Division medication relationship. Results In the 39 liver transplant recipients, there were 12 cases of CYP3A5: * 3 / * 3 genotypes, 8 cases of * 1 / * 3 type, 19 cases of * 1 / * 1 type, 13 cases of MDR1: T / T type in 18 cases, C / C type in 8 cases. Conclusion The polymorphism of CYP3A5 gene in liver transplant recipients is correlated with the plasma concentration of tacrolimus in recipients. To study CYP3A5 donor gene polymorphism is helpful for the development of individualized tacrolimus regimen in patients after transplantation. However, donor MDR1 gene has little effect on the individualization of Tacrolimus receptor.